Hear from our CEO, Adrian Treverton, about treating non-melanoma skin cancer patients safely during COVID. Patients most likely to develop basal or squamous cell carcinoma are those in the age range at greater risk of serious illness from COVID, so safe and short treatment options are important.
Xstrahl Announces Live Demos of Radiant™ AURA and XBeam V2 at AAD 2026
Xstrahl, a global leader in the delivery of superficial and orthovoltage radiation therapy and preclinical radiation research systems, will feature Radiant™ Aura with XBeam treatment planning at the annual meeting of the American Academy of Dermatology (AAD), in Orlando, FL, from March 7-9, 2025 (Booth #2975).
